8.2
CiteScore
6.6
Impact Factor
Volume 50 Issue 12
Dec.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Genetics and Genomics  > 2023  >  50(12): 934-947

Humoral and cellular immunity against diverse SARS-CoV-2 variants

doi: 10.1016/j.jgg.2023.10.003
  •  

    Center for Infectious Disease Research, School of Life Science, Westlake University, Hangzhou, Zhejiang 310001, China

Funds:

Additionally, we appreciate the financial support provided by Westlake University and Westlake Laboratory.

  • Received Date: 2023-06-29
  • Accepted Date: 2023-10-10
  • Rev Recd Date: 2023-09-27
    • Available Online: 2025-06-07
  • Publish Date: 2023-10-19
    Abstract
  • Since the outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019, the virus has rapidly spread worldwide. This has led to an unprecedented global pandemic, marked by millions of COVID-19 cases and a significant number of fatalities. Over a relatively short period, several different vaccine platforms are developed and deployed for use globally to curb the pandemic. However, the genome of SARS-CoV-2 continuously undergoes mutation and/or recombination, resulting in the emergence of several variants of concern (VOC). These VOCs can elevate viral transmission and evade the neutralizing antibodies induced by vaccines, leading to reinfections. Understanding the impact of the SARS-CoV-2 genomic mutation on viral pathogenesis and immune escape is crucial for assessing the threat of new variants to public health. This review focuses on the emergence and pathogenesis of VOC, with particular emphasis on their evasion of neutralizing antibodies. Furthermore, the memory B cell, CD4+, and CD8+ T cell memory induced by different COVID-19 vaccines or infections are discussed, along with how these cells recognize VOC. This review summarizes the current knowledge on adaptive immunology regarding SARS-CoV-2 infection and vaccines. Such knowledge may also be applied to vaccine design for other pathogens.
    • FullText(HTML)
  • loading
    • References(166)
  • Abayasingam, A., Balachandran, H., Agapiou, D., Hammoud, M., Rodrigo, C., Keoshkerian, E., Li, H., Brasher, N.A., Christ, D., Rouet, R., et al., 2021. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. 2, 100228.
    Abu-Raddad, L.J., Chemaitelly, H., Butt, A.A., Vaccination, N.S.G. for C.-19, 2021. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187-189.
    Accorsi, E.K., Britton, A., Fleming-Dutra, K.E., Smith, Z.R., Shang, N., Derado, G., Miller, J., Schrag, S.J., Verani, J.R., 2022. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 327, 639-651.
    Alenquer, M., Ferreira, F., Lousa, D., Valerio, M., Medina-Lopes, M., Bergman, M.-L., Goncalves, J., Demengeot, J., Leite, R.B., Lilue, J., Ning, Z., et al., 2021. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. 17, e1009772.
    Aliprantis, A.O., Shaw, C.A., Griffin, P., Farinola, N., Railkar, R.A., Cao, X., Liu, W., Sachs, J.R., Swenson, C.J., Lee, H., et al., 2021. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. 17, 1248-1261.
    Altarawneh, H.N., Chemaitelly, H., Hasan, M.R., Ayoub, H.H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H.M., Al-Khatib, H.A., Benslimane, F.M., et al., 2022. Protection against the Omicron variant from previous SARS-CoV-2 infection. N. Engl. J. Med. 386, 1288-1290.
    Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., Garcia-Sastre, A., Krammer, F., 2021. Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. mBio 12, e02648-20.
    Andeweg, S.P., de Gier, B., Eggink, D., van den Ende, C., van Maarseveen, N., Ali, L., Vlaemynck, B., Schepers, R., Hahne, S.J.M., Reusken, C.B.E.M., et al., 2022. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat. Commun. 13, 4738.
    Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., et al., 2021. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature 600, 530-535.
    Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O'Connell, A.-M., Simons, D., et al., 2022. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532-1546.
    Atmar, R.L., Lyke, K.E., Deming, M.E., Jackson, L.A., Branche, A.R., Sahly, H.M.E., Rostad, C.A., Martin, J.M., Johnston, C., Rupp, R.E., et al., 2022. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med. 386, 1046-1057.
    Bae, S., Kim, S.R., Kim, M.-N., Shim, W.J., Park, S.-M., 2021. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart 107, 373-380.
    Barouch, D.H., Stephenson, K.E., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K., Liu, J., Chandrashekar, A., Patel, S., Gars, M.L., et al., 2021. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N. Engl. J. Med. 385, 951-953.
    Bates, T.A., McBride, S.K., Leier, H.C., Guzman, G., Lyski, Z.L., Schoen, D., Winders, B., Lee, J.-Y., Lee, D.X., Messer, W.B., et al., 2022. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. 7, eabn8014.
    Bert, N.L., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., et al., 2020. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457-462.
    Bert, N.L., Clapham, H.E., Tan, A.T., Chia, W.N., Tham, C.Y.L., Lim, J.M., Kunasegaran, K., Tan, L.W.L., Dutertre, C.-A., Shankar, N., et al., 2021. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 218, e20202617.
    Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M., Premji, Z., Issa, H., et al., 2023. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect. Dis. 23, 556-567.
    Bolze, A., Luo, S., White, S., Cirulli, E.T., Wyman, D., Rossi, A.D., Machado, H., Cassens, T., Jacobs, S., Barrett, K.M.S., et al., 2022. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. 3, 100564.
    Bowen, J.E., Addetia, A., Dang, H.V., Stewart, C., Brown, J.T., Sharkey, W.K., Sprouse, K.R., Walls, A.C., Mazzitelli, I.G., Logue, J.K., et al., 2022. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science 377, 890-894.
    Butt, A.A., Dargham, S.R., Chemaitelly, H., Khal, A.A., Tang, P., Hasan, M.R., Coyle, P.V., Thomas, A.G., Borham, A.M., Concepcion, E.G., et al., 2022. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. 182, 197-205.
    Campos, G.R.F., Almeida, N.B.F., Filgueiras, P.S., Corsini, C.A., Gomes, S.V.C., Miranda, D.A.P. de, Assis, J.V. de, Silva, T.B. S., Alves, P.A., Fernandes, G. da R., et al., 2022. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. Commun. Med. 2, 76.
    Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, Xiaofeng, Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al., 2021. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. 31, 732-741.
    Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al., 2022. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593-602.
    Carreno, J.M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A.J., Kawabata, H., Sominsky, L.A., Clark, J.J., Adelsberg, D.C., Bielak, D.A., et al., 2022. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682-688.
    Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al., 2021. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature 593,142-146.
    Cele, S., Bernstein, M., Karim, F., Khan, K., Ganga, Y., Jule, Z., Reedoy, K., Lustig, G., Samsunder, N., Mazibuko, M., et al., 2022. Beta infection combined with Pfizer BNT162b2 vaccination leads to broadened neutralizing immunity against Omicron. 2022.04.15.22273711.
    Chan, J.F.-W., Kok, K.-H., Zhu, Z., Chu, H., To, K.K.-W., Yuan, S., Yuen, K.-Y., 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. 9, 221-236.
    Chen, Z., Wherry, E.J., 2020. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 20, 529-536.
    Chen, Y., Shen, H., Huang, R., Tong, X., Wu, C., 2021. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac. Lancet Infect. Dis. 21, 1071-1072.
    Cheon, I. S., Li, C., Son, Y. M., Goplen, N. P., Wu, Y., Cassmann, T., Wang, Z., Wei, X., Tang, J., Li, Y., et al., 2021. Immune signatures underlying post-acute COVID-19 lung sequelae. 6, eabk1741.
    Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al., 2021. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517-522.
    Cohen, K.W., Linderman, S.L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, C., Nyhoff, L.E., Edara, V.V., Floyd, K., et al., 2021. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. 2, 100354.
    COVID-19 Forecasting Team, 2023. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 401, 833-842.
    Crotty, S., 2019. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132-1148.
    Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., Ahmed, R., 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973.
    Dacon, C., Tucker, C., Peng, L., Lee, C.-C.D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L., Purser, L., Williams, J.K., et al., 2022. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728-735.
    Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I., Haupt, S., Frazier, A., et al., 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063.
    Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al., 2021. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939-2954.
    Dejnirattisai, W., Huo, J., Zhou, D., Zahradnik, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E., Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., et al., 2022. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467-484.
    Dugan, H.L., Stamper, C.T., Li, L., Changrob, S., Asby, N.W., Halfmann, P.J., Zheng, N.-Y., Huang, M., Shaw, D.G., Cobb, M.S., et al., 2021. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 54, 1290-1303.
    Eckerle, L.D., Becker, M.M., Halpin, R.A., Li, K., Venter, E., Lu, X., Scherbakova, S., Graham, R.L., Baric, R.S., Stockwell, T.B., et al., 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. 6, e1000896.
    Edara, V.V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M.E., Hudson, W.H., Mantus, G., Nyhoff, L.E., Adelman, M.W., Fineman, R., et al., 2021. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 29, 516-521.e3.
    Edridge, A.W.D., Kaczorowska, J., Hoste, A.C.R., Bakker, M., Klein, M., Loens, K., Jebbink, M.F., Matser, A., Kinsella, C.M., Rueda, P., et al., 2020. Seasonal coronavirus protective immunity is short-lasting. 26, 1691-1693.
    Ferdinands, J.M., Rao, S., Dixon, B.E., Mitchell, P.K., DeSilva, M.B., Irving, S.A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S.J., et al., 2022. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 379, e072141.
    Files, J.K., Boppana, S., Perez, M.D., Sarkar, S., Lowman, K.E., Qin, K., Sterrett, S., Carlin, E., Bansal, A., Sabbaj, S., et al., 2020. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J. Clin. Invest. 131, e140491.
    Gao, Y., Cai, C., Grifoni, A., Muller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Osterborg, A., Bergman, P., et al., 2022. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. 28, 472-476.
    Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J., Hauser, B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al., 2021. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476-488.
    Garcia-Beltran, W.F., Denis, K.J.St, Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., et al., 2022. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457-466.
    Gazit, S., Mizrahi, B., Kalkstein, N., Neuberger, A., Peretz, A., Mizrahi-Reuveni, M., Ben-Tov, A., Patalon, T., 2021. BNT162b2 mRNA vaccine effectiveness given confirmed exposure: analysis of household members of COVID-19 patients. Clin. Infect. Dis. 75, e734-e740.
    Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen, K.A., Reynaldi, A., Khoury, D.S., Ajinkya, P., et al., 2021. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829.
    Graham, M.S., Sudre, C.H., May, A., Antonelli, M., Murray, B., Varsavsky, T., Klaser, K., Canas, L.S., Molteni, E., Modat, M.,et al., 2021. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 6, e335-e345.
    Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L.E., Klein, F., 2022. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. 28, 477-480.
    Halfmann, P.J., Iida, S., Iwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S.M., Darling, T.L., Joshi, A., Loeber, S., Singh, G., et al., 2022. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687-692.
    Hartley, G.E., Edwards, E.S.J., Aui, P.M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A.Y., Boo, I., Drummer, H.E., Hogarth, P.M., et al., 2020. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. 5, eabf8891.
    Heath, P.T., Galiza, E.P., Baxter, D.N., Boffito, M., Browne, D., Burns, F., Chadwick, D.R., Clark, R., Cosgrove, C., Galloway, J., et al., 2021. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172-1183.
    Hirano, M., Guo, P., McCurley, N., Schorpp, M., Das, S., Boehm, T., Cooper, M.D., 2013. Evolutionary implications of a third lymphocyte lineage in lampreys. Nature 501, 435-438.
    Hitchings, M.D.T., Ranzani, O.T., Torres, M.S.S., Oliveira, S.B., Almiron, M., Said, R., Borg, R., Schulz, W.L., Oliveira, R.D. de, Silva, P.V. da, et al., 2021. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study. 1, 100025.
    Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.-H., Nitsche, A., et al., 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.
    Hu, Z., Huang, X., Zhang, J., Fu, S., Ding, D., Tao, Z., 2022. Differences in clinical characteristics between Delta variant and wild-Type SARS-CoV-2 infected patients. Front. Med. 8, 792135.
    Imai, M., Halfmann, P.J., Yamayoshi, S., Iwatsuki-Horimoto, K., Chiba, S., Watanabe, T., Nakajima, N., Ito, M., Kuroda, M., Kiso, M., et al., 2021. Characterization of a new SARS-CoV-2 variant that emerged in Brazil. 118, e2106535118.
    Ito, J., Suzuki, R., Uriu, K., Itakura, Y., Zahradnik, J., Kimura, K.T., Deguchi, S., Wang, L., Lytras, S., Tamura, T., et al., 2023. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 14, 2671.
    Jackson, C.B., Farzan, M., Chen, B., Choe, H., 2022. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3-20.
    Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al., 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-716.
    Karim, S.S.A., Karim, Q.A., 2021. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126-2128.
    Khan, K., Karim, F., Cele, S., Reedoy, K., San, J.E., Lustig, G., Tegally, H., Rosenberg, Y., Bernstein, M., Jule, Z., et al., 2022. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature 607, 356-359.
    Khoo, N.K.H., Lim, J.M.E., Gill, U.S., de Alwis, R., Tan, N., Toh, J.Z.N., Abbott, J.E., Usai, C., Ooi, E.E., Low, J.G.H., et al., 2022. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. 3, 104-118.
    Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K., Kent, S.J., Triccas, J.A., Davenport, M.P., 2021. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. 27, 1205-1211.
    Klingler, J., Weiss, S., Itri, V., Liu, X., Oguntuyo, K.Y., Stevens, C., Ikegame, S., Hung, C.-T., Enyindah-Asonye, G., Amanat, F., et al., 2021. Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome Coronavirus 2. J. Infect. Dis. 223, 957-970.
    Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., et al., 2022. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. 7, eabn8590.
    Ku, Z., Xie, X., Hinton, P.R., Liu, X., Ye, X., Muruato, A.E., Ng, D.C., Biswas, S., Zou, J., Liu, Y., et al., 2021. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature 595, 718-723.
    Kusnadi, A., Ramirez-Suastegui, C., Fajardo, V., Chee, S.J., Meckiff, B.J., Simon, H., Pelosi, E., Seumois, G., Ay, F., Vijayanand, P., et al., 2021. Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8+ T cells. 6, eabe4782.
    Law, J.C., Girard, M., Chao, G.Y.C., Ward, L.A., Isho, B., Rathod, B., Colwill, K., Li, Z., Rini, J.M., Yue, F.Y., et al., 2022. Persistence of T cell and antibody responses to SARS-CoV-2 up to 9 Months after symptom onset. J. Immunol. 208, 429-443.
    Lee, J.H., Sutton, H.J., Cottrell, C.A., Phung, I., Ozorowski, G., Sewall, L.M., Nedellec, R., Nakao, C., Silva, M., Richey, S.T., et al., 2022. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998-1004.
    Lempp, F.A., Soriaga, L.B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y.-J., Bianchi, S., Walls, A.C., Bowen, J.E., Zhou, J., et al., 2021. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342-347.
    Li, D., Edwards, R.J., Manne, K., Martinez, D.R., Schafer, A., Alam, S.M., Wiehe, K., Lu, X., Parks, R., Sutherland, L.L., et al., 2021a. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203-4219.
    Li, Q., Nie, J., Wu, J., Zhang, Li, Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al., 2021b. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184, 2362-2371.
    Li, B., Deng, A., Li, K., Hu, Y., Li, Z., Shi, Y., Xiong, Q., Liu, Z., Guo, Q., Zou, L., et al., 2022. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nat. Commun. 13, 460.
    Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A.J., Zhao, Y., et al., 2021a. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220-4236.
    Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S.C., Swanson, K.A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al., 2021b. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273-275.
    Low, J.S., Jerak, J., Tortorici, M.A., McCallum, M., Pinto, D., Cassotta, A., Foglierini, M., Mele, F., Abdelnabi, R., Weynand, B., et al., 2022. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science. 377, 735-742.
    Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565-574.
    Ma, C., Sun, W., Tang, T., Jia, M., Liu, Y., Wan, Y., Han, J., Rodewald, L., Li, J., Song, Y., Wang, Y., et al., 2022. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021. Vaccine 40, 2869-2874.
    Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K., Barnabas, S.L., Bhorat, Q.E., et al., 2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885-1898.
    Mateus, J., Dan, J.M., Zhang, Z., Moderbacher, C.R., Lammers, M., Goodwin, B., Sette, A., Crotty, S., Weiskopf, D., 2021. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science 374, eabj9853.
    Mazzoni, A., Lauria, N.D., Maggi, L., Salvati, L., Vanni, A., Capone, M., Lamacchia, G., Mantengoli, E., Spinicci, M., Zammarchi, L., et al., 2021. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in recovered COVID-19 subjects. J. Clin. Invest. 131, e149150.
    McCallum, M., Marco, A.D., Lempp, F.A., Tortorici, M.A., Pinto, D., Walls, A.C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al., 2021. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332-2347.
    McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al., 2021. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630-634.
    Meng, B., Abdullahi, A., Ferreira, I.A.T.M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P.P., Fatihi, S., Rathore, S., et al., 2022. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706-714.
    Mlcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., Singh, S., et al., 2021. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114-119.
    Moderbacher, C.R., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D., Belanger, S., Abbott, R.K., Kim, Christina, Choi, J., et al., 2020. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996-1012.
    Nachbagauer, R., Feser, J., Naficy, A., Bernstein, D.I., Guptill, J., Walter, E.B., Berlanda-Scorza, F., Stadlbauer, D., Wilson, P.C., Aydillo, T., et al., 2021. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. 27, 106-114.
    Naranbhai, V., Garcia-Beltran, W.F., Chang, C.C., Mairena, C.B., Thierauf, J.C., Kirkpatrick, G., Onozato, M.L., Cheng, J., Denis, K.J.S., Lam, E.C., et al., 2022a. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines. J. Infect. Dis. 225, 1141-1150.
    Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., Tano-Menka, R., Ofoman, O., Gayton, A., et al., 2022b. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1041-1051.
    Nordstrom, P., Ballin, M., Nordstrom, A., 2022. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect. Dis. 22, 781-790.
    Notarbartolo, S., Ranzani, V., Bandera, A., Gruarin, P., Bevilacqua, V., Putignano, A.R., Gobbini, A., Galeota, E., Manara, C., Bombaci, M., et al., 2021. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. 6, eabg5021.
    Nyberg, T., Ferguson, N.M., Nash, S.G., Webster, H.H., Flaxman, S., Andrews, N., Hinsley, W., Bernal, J.L., Kall, M., Bhatt, S., et al., 2022. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 399, 1303-1312.
    Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C., Angeletti, S., Ciccozzi, M., Gallo, R.C., et al., 2020. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J. Transl. Med. 18, 179.
    Park, Y.-J., Pinto, D., Walls, A.C., Liu, Z., Marco, A.D., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K.R., et al., 2022. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science 378, 619-627.
    Peng, Y., Felce, S.L., Dong, D., Penkava, F., Mentzer, A.J., Yao, X., Liu, G., Yin, Z., Chen, J.-L., Lu, Y., et al., 2022. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 23, 50-61.
    Piccoli, L., Park, Y.-J., Tortorici, M.A., Czudnochowski, N., Walls, A.C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L.E., Bowen, J.E., et al., 2020. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-uided high-esolution erology. Cell 183, 1024-1042.
    Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M.M., Bishop, E., et al., 2021a. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. 27, 917-924.
    Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al., 2021b. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276-280.
    Poon, M.M.L., Rybkina, K., Kato, Y., Kubota, M., Matsumoto, R., Bloom, N.I., Zhang, Z., Hastie, K.M., Grifoni, A., Weiskopf, D., et al., 2021. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. 6, eabl9105.
    Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Neshin, S.A.S., Khatami, A., Turner, D.L., Djalalinia, S., Mousavi, S.A., Mardani-Fard, H.A., et al., 2021. Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. 10, 23.
    Puhach, O., Adea, K., Hulo, N., Sattonnet, P., Genecand, C., Iten, A., Jacquerioz, F., Kaiser, L., Vetter, P., Eckerle, I., et al., 2022. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. 28, 1491-1500.
    Qu, P., Evans, J.P., Zheng, Y.-M., Carlin, C., Saif, L.J., Oltz, E.M., Xu, K., Gumina, R.J., Liu, S.-L., 2022a. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Cell Host Microbe 30, 1518-1526.
    Qu, P., Faraone, J.N., Evans, J.P., Zheng, Y.-M., Yu, L., Ma, Q., Carlin, C., Lozanski, G., Saif, L.J., Oltz, E.M., et al., 2022b. Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants. N. Engl. J. Med. 387, 1329-1331.
    Qu, P., Evans, J.P., Faraone, J.N., Zheng, Y.-M., Carlin, C., Anghelina, M., Stevens, P., Fernandez, S., Jones, D., Lozanski, G., et al., 2023. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe 31, 9-17.
    Quandt, J., Muik, A., Salisch, N., Lui, B.G., Lutz, S., Kruger, K., Wallisch, A.-K., Adams-Quack, P., Bacher, M., Finlayson, A., et al., 2022. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. 7, eabq2427.
    Rha, M.-S., Jeong, H.W., Ko, J.-H., Choi, S.J., Seo, I.-H., Lee, J.S., Sa, M., Kim, A.R., Joo, E.-J., Ahn, J.Y., et al., 2021. PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19. Immunity 54, 44-52.
    Rice, B.L., Annapragada, A., Baker, R.E., Bruijning, M., Dotse-Gborgbortsi, W., Mensah, K., Miller, I.F., Motaze, N.V., Raherinandrasana, A., Rajeev, M., et al., 2021. Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. 27, 447-453.
    Sadoff, J., Gray, G., Vandebosch, A., Cardenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., et al., 2021. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187-2201.
    Sagar, M., Reifler, K., Rossi, M., Miller, N.S., Sinha, P., White, L., Mizgerd, J.P., 2020. Recent endemic coronavirus infection is associated with less severe COVID-19. J. Clin. Invest. 131, e143380.
    Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., et al., 2022. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature 602, 300-306.
    Sakharkar, M., Rappazzo, C.G., Wieland-Alter, W.F., Hsieh, C.-L., Wrapp, D., Esterman, E.S., Kaku, C.I., Wec, A.Z., Geoghegan, J.C., McLellan, J.S., et al., 2021. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. 6, eabg6916.
    Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., Li, F., 2020. Cell entry mechanisms of SARS-CoV-2. 117, 11727-11734.
    Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al., 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science 368, 1016-1020.
    Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M.S.L., Moodley, D., Hanley, S., et al., 2021. Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1899-1909.
    Shuai, H., Chan, J.F.-W., Hu, B., Chai, Y., Yuen, T.T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C., Liu, H., et al., 2022. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693-699.
    Sokal, A., Barba-Spaeth, G., Fernandez, I., Broketa, M., Azzaoui, I., Selle, A. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al., 2021a. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893-2907.
    Sokal, A., Chappert, P., Barba-Spaeth, G., Roeser, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Fernandez, I., Meola, A., Bouvier-Alias, M., et al., 2021b. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201-1213.
    Souza, W.M., Amorim, M.R., Sesti-Costa, R., Coimbra, L.D., Brunetti, N.S., Toledo-Teixeira, D.A., de Souza, G.F., Muraro, S.P., Parise, P.L., Barbosa, P.P., et al., 2021. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. 2, 527-535.
    Starr, T.N., Greaney, A.J., Hilton, S.K., Ellis, D., Crawford, K.H.D., Dingens, A.S., Navarro, M.J., Bowen, J.E., Tortorici, M.A., Walls, A.C.,et al., 2020. Deep mutational canning of SARS-CoV-2 receptor binding domain reveals onstraints on folding and ACE2 binding. Cell 182, 1295-1310.
    Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claer, L., Quentric, P., Fadlallah, J., Devilliers, H., Ghillani, P., et al., 2021. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223.
    Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y., Nao, N., Nasser, H., Uriu, K., et al., 2022. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature 603, 700-705.
    Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C., Gibbons, J.M., Bert, N.L., Tan, A.T., et al., 2022. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110-117.
    Szabo, P.A., Dogra, P., Gray, J.I., Wells, S.B., Connors, T.J., Weisberg, S.P., Krupska, I., Matsumoto, R., Poon, M.M.L., Idzikowski, E., et al., 2021. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity 54, 797-814.e6.
    Tamura, T., Ito, J., Uriu, K., Zahradnik, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S., et al., 2023. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat. Commun. 14, 2800.
    Tan, A.T., Linster, M., Tan, C.W., Bert, N.L., Chia, W.N., Kunasegaran, K., Zhuang, Y., Tham, C.Y.L., Chia, A., Smith, G.J.D., et al., 2021a. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. 34, 108728.
    Tan, C.-W., Chia, W.-N., Young, B.E., Zhu, F., Lim, B.-L., Sia, W.-R., Thein, T.-L., Chen, M.I.-C., Leo, Y.-S., Lye, D.C., et al., 2021b. Pan-sarbecovirus neutralizing antibodies in BNT162b2-mmunized SARS-CoV-1 urvivors. N. Engl. J. Med. 385, 1401-1406.
    Tarke, A., Sidney, J., Kidd, C.K., Dan, J.M., Ramirez, S.I., Yu, E.D., Mateus, J., Antunes, R. da S., Moore, E., Rubiro, P., et al., 2021. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. 2, 100204.
    Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin, B., Phillips, E., Mallal, S., et al., 2022. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847-859.
    Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E.J., Msomi, N., et al., 2021. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438-443.
    Tian, D., Sun, Y., Zhou, J., Ye, Q., 2021. The global epidemic of the SARS-CoV-2 Delta variant, key spike mutations and immune escape. Front. Immunol. 12, 751778.
    Tseng, H.F., Ackerson, B.K., Luo, Y., Sy, L.S., Talarico, C.A., Tian, Y., Bruxvoort, K.J., Tubert, J.E., Florea, A., Ku, J.H., et al., 2022. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. 28, 1063-1071.
    Tseng, H.F., Ackerson, B.K., Bruxvoort, K.J., Sy, L.S., Tubert, J.E., Lee, G.S., Ku, J.H., Florea, A., Luo, Y., Qiu, S., et al., 2023. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 14, 189.
    Turner, J.S., Zhou, J.Q., Han, J., Schmitz, A.J., Rizk, A.A., Alsoussi, W.B., Lei, T., Amor, M., McIntire, K.M., Meade, P., et al., 2020. Human germinal centres engage memory and naive B cells after influenza vaccination. Nature 586, 127-132.
    Turner, J.S., O'Halloran, J.A., Kalaidina, E., Kim, W., Schmitz, A.J., Zhou, J.Q., Lei, T., Thapa, M., Chen, R.E., Case, J.B., et al., 2021. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109-113.
    Twohig, K.A., Nyberg, T., Zaidi, A., Thelwall, S., Sinnathamby, M.A., Aliabadi, S., Seaman, S.R., Harris, R.J., Hope, R., Lopez-Bernal, J., et al., 2022. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect. Dis. 22, 35-42.
    Ueda, G., Antanasijevic, A., Fallas, J.A., Sheffler, W., Copps, J., Ellis, D., Hutchinson, G.B., Moyer, A., Yasmeen, A., Tsybovsky, Y., et al., 2020. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. Elife 9, e57659.
    Vikkurthi, R., Ansari, A., Pai, A.R., Jha, S.N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B.P., Parray, H.A., et al., 2022. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. 7, 974-985.
    Volz, E., Mishra, S., Chand, M., Barrett, J.C., Johnson, R., Geidelberg, L., Hinsley, W.R., Laydon, D.J., Dabrera, G., O'Toole, A., et al., 2021. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266-269.
    Walls, A.C., Fiala, B., Schafer, A., Wrenn, S., Pham, M.N., Murphy, M., Tse, L.V., Shehata, L., O'Connor, M.A., Chen, C., et al., 2020a. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367-1382.
    Walls, A.C., Park, Y.-J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., 2020b. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281-292.
    Walls, A.C., Sprouse, K.R., Bowen, J.E., Joshi, A., Franko, N., Navarro, M.J., Stewart, C., Cameroni, E., McCallum, M., Goecker, E.A., et al., 2022. SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses. Cell 185, 872-880.
    Wang, G.-L., Wang, Z.-Y., Duan, L.-J., Meng, Q.-C., Jiang, M.-D., Cao, J., Yao, L., Zhu, K.-L., Cao, W.-C., Ma, M.-J., 2021a. Susceptibility of circulating SARS-CoV-2 variants to neutralization. N. Engl. J. Med. 384, 2354-2356.
    Wang, P., Casner, R.G., Nair, M.S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P.D., Huang, Y., Shapiro, L., et al., 2021b. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe 29, 747-751.
    Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Viant, C., Gaebler, C., Cipolla, M., Hoffmann, H.-H., Oliveira, T.Y., Oren, D.A., et al., 2021c. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555.
    Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H.-H., Barnes, C.O., Cipolla, M., Ramos, V., et al., 2021d. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426-431.
    Wang, K., Jia, Z., Bao, L., Wang, L., Cao, L., Chi, H., Hu, Y., Li, Q., Zhou, Y., Jiang, Y., et al., 2022. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature 603, 919-925.
    Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al., 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. 27, 622-625.
    Widge, A.T., Hofstetter, A.R., Houser, K.V., Awan, S.F., Chen, G.L., Florez, M.C.B., Berkowitz, N.M., Mendoza, F., Hendel, C.S., Holman, L.A., et al., 2023. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790.
    Wragg, K.M., Lee, W.S., Koutsakos, M., Tan, H.-X., Amarasena, T., Reynaldi, A., Gare, G., Konstandopoulos, P., Field, K.R., Esterbauer, R., et al., 2022. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nat. Immunol. 23, 768-780.
    Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.-Y., Mays, I., Garman, L., Helms, C., et al., 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671.
    Wu, Z., McGoogan, J.M., 2020. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 323, 1239-1242.
    Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al., 2020. A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269.
    Yadav, P.D., Sapkal, G.N., Ella, R., Sahay, R.R., Nyayanit, D.A., Patil, D.Y., Deshpande, G., Shete, A.M., Gupta, N., Mohan, V.K., et al., 2021. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. 28, taab104.
    Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., Sato, K., Consortium, G. to P.J., 2022. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect. Dis. 22, 942-943.
    Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., Zhou, Q., 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444-1448.
    Yang, S., Li, Y., Dai, L., Wang, J., He, P., Li, C., Fang, X., Wang, C., Zhao, X., Huang, E., et al., 2021. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107-1119.
    Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al., 2022. Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. Nat. Commun. 13, 1788.
    Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Galvez, R.I., Cortes, F.H., Grifoni, A., Tarke, A., Chang, J., et al., 2022. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434-2451.
    Zhao, X., Chen, D., Szabla, R., Zheng, M., Li, G., Du, P., Zheng, S., Li, X., Song, C., Li, R., et al., 2020. Broad and differential animal angiotensin-converting enzyme 2 receptor usage by SARS-CoV-2. J. Virol. 94, e00940-20.
    Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.
    Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al., 2020. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727-733.
    Zuo, J., Dowell, A.C., Pearce, H., Verma, K., Long, H.M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al., 2021. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 22, 620-626.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF

    Article Metrics

    Article views (0) PDF downloads (0) Cited by ()
    Proportional views
    Related

    Editorial Office

    Journal of Genetics and Genomics

    京ICP备09063187号-12

    No.1, West Beichen Road, Chaoyang District, Beijing 100101, P.R.China

    +86-10-64806528+86-10-64807786jgg@genetics.ac.cn

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return